Sales & Marketing

Teams aim to develop numerous degrader-antibody conjugates to selectively kill cancer cells.

Company aims to improve access to WHO-recommended pediatric regimen for children with HIV in low- and middle-income countries.

The implications of Twitter’s rebrand for healthcare marketing.

A phased launch approach may ultimately be more sustainable and enable maximum market penetration and commercial success with less upfront investment than traditional “go-for-broke” strategies.

Collaboration to pair artificial intelligence proficiencies with clinical research expertise.

Biopharma company now required to seek approval before attempting further buyouts.

Shift comes with $5 million dedication to launch Cencora’s healthier futures grant program.

The drug is now indicated for adults with low-risk myelodysplastic syndromes.

Treatment indicated for babies under two months old with spinal muscular atrophy.

A five-step pilot approach to effective measurement of medical affairs omnichannel efforts.

Delay to allow agency to consider other ways of solving the issue, filing says.

Deal includes all issued and outstanding securities.

Collaboration to focus on digital therapeutics.

Pharma company to pay a fine of $225 million over five years.

Program designed to aid life science organizations in improving go-to-market strategy.

Webinar Date/Time: Tuesday, September 19th, 2023 at 8am PDT | 11am EDT | 4pm BST

Amid Twitter's transformation into "X", social media expert Mikaela Walker weighs in on the rebrand's impact for pharma marketing, assesses ongoing brand safety risks, and highlights established social platforms and those gaining traction.

Medication is the first approved in wAMD and DME for immediate dosing at 8-week and up to 16-week intervals following three initial monthly doses.

Bispecific therapy indicated for the treatment of relapsed and refractory multiple myeloma.

Delays could harm older Americans, interest group states.

Medicine designated for the treatment of children and adults with chaple disease.

Treatment indicated as the first and only for patients with fibrodysplasia ossificans progressiva.

Deal includes potential additional payments of up to $140 million.

Partnership aims to enhance therapeutic benefit and safety.

The FDA's OPDP has sternly cautioned AstraZeneca for misleading claims in the promotional materials of its Breztri Aerosphere inhalation aerosol.